Scendea
Paul Cronin is an experienced professional in the pharmaceutical and biotechnology industry, currently serving as the Director at Scendea since May 2020. Prior to this role, Paul was the Director at Clinical Network Services until its rebranding to Scendea in June 2020 and also contributed as an Advisory Board Member at BioPartner UK from April 2019 to August 2021. Previous positions include Director of Business Development at Diamond Pharma Services and Business Development Manager at Smerud Medical Research, along with a notable tenure at ERA Consulting (UK) Ltd. Paul has editorial experience as a Consultant Editor for the TOPRA journal, Regulatory Rapporteur. Paul holds an MSc in International Business and Management from Alliance Manchester Business School and a BSc in Biochemistry from The University of Manchester.
This person is not in any offices
Scendea
Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs. A combination of scientific excellence, industry experience and a collaborative approach enable us to deliver high-quality innovative solutions, which allow our clients to succeed. Our award-winning international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval.